Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy
- PMID: 17362318
- DOI: 10.1111/j.1525-1438.2006.00766.x
Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy
Abstract
Paclitaxel combined with carboplatin is currently accepted as the first-line treatment for ovarian carcinoma, frequently associated with neuropathy. Due to its frequent association with neuropathy, combination of docetaxel and carboplatin has been suggested as an alternative. A 47-year-old woman developed paresthesia after the first cycle of paclitaxel/carboplatin for ovarian cancer. Her nerve conduction study (NCS) showed only sural neuropathy after completion of six cycles, which returned to normal in 6 months. She had fewer neuropathy symptoms when treatment was changed to docetaxel/carboplatin for recurrent cancer. NCS revealed generalized sensory neuropathy following docetaxel/carboplatin treatment, which normalized after 12 months. Our observation indicated that there is a disparity between clinical symptoms and electrophysiologic examination in taxane-induced neuropathy. Although docetaxel was tolerated well by the patient, evidence of generalized sensory neuropathy was present in NCS.
Similar articles
-
Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.JAMA Oncol. 2019 Jun 1;5(6):833-840. doi: 10.1001/jamaoncol.2019.0001. JAMA Oncol. 2019. PMID: 30896757 Free PMC article. Clinical Trial.
-
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.Int J Clin Oncol. 2013 Feb;18(1):126-31. doi: 10.1007/s10147-011-0353-9. Epub 2011 Nov 30. Int J Clin Oncol. 2013. PMID: 22127346 Clinical Trial.
-
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.BMC Cancer. 2014 Dec 11;14:937. doi: 10.1186/1471-2407-14-937. BMC Cancer. 2014. PMID: 25494701 Free PMC article. Clinical Trial.
-
Docetaxel: an alternative taxane in ovarian cancer.Br J Cancer. 2003 Dec;89 Suppl 3(Suppl 3):S9-S15. doi: 10.1038/sj.bjc.6601495. Br J Cancer. 2003. PMID: 14661041 Free PMC article. Review.
-
Current status of taxane and platinum-based chemotherapy in ovarian cancer.J Clin Oncol. 2003 May 15;21(10 Suppl):133s-135s. doi: 10.1200/JCO.2003.01.066. J Clin Oncol. 2003. PMID: 12743128 Review.
Cited by
-
Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat.J Pain. 2009 May;10(5):534-41. doi: 10.1016/j.jpain.2008.12.003. Epub 2009 Feb 23. J Pain. 2009. PMID: 19231296 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical